Axsome Therapeutics, Inc.AXSMNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank60
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-26.32%
↑ 70% vs avg
Percentile
P60
Within normal range
Streak
3 yr
Consecutive growthExpanding
Average
-88.45%
Historical baseline
PeriodValueYoY Change
2025-26.32%+62.8%
2024-70.68%+15.0%
2023-83.15%+76.3%
2022-350.53%-
20210.00%-
20130.00%-